Compulsory licensing under TRIPS means that India can allow manufacturing without running afoul of international trade law, though if enough non-Indians started doing this it could cause some headaches due to the "predominantly for domestic use" clause. But in reality there's no way that pharma companies can stop developing countries from manufacturing critical medicines.